Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.205 USD | +9.45% | +0.15% | +13.64% |
Valuation
Fiscal Period: March | 2019 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|
Capitalization 1 | 11.26 | 4.539 | 3.2 | - | - |
Enterprise Value (EV) 1 | 11.26 | 4.539 | 3.2 | 3.2 | 3.2 |
P/E ratio | -0.66 x | -0.64 x | -0.23 x | -0.46 x | -1.58 x |
Yield | - | - | - | - | - |
Capitalization / Revenue | 0.59 x | - | 0.22 x | 0.18 x | 0.14 x |
EV / Revenue | 0.59 x | - | 0.22 x | 0.18 x | 0.14 x |
EV / EBITDA | - | - | - | - | - |
EV / FCF | - | - | - | - | - |
FCF Yield | - | - | - | - | - |
Price to Book | - | - | - | - | - |
Nbr of stocks (in thousands) | 1,330 | 4,649 | 15,607 | - | - |
Reference price 2 | 8.461 | 0.9763 | 0.2050 | 0.2050 | 0.2050 |
Announcement Date | 7/1/19 | 6/21/23 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: March | 2019 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|
Net sales 1 | 18.97 | - | 14.7 | 17.9 | 22.1 |
EBITDA | - | - | - | - | - |
EBIT 1 | -11.26 | - | -4.61 | -3.36 | -1.3 |
Operating Margin | -59.35% | - | -31.36% | -18.77% | -5.88% |
Earnings before Tax (EBT) 1 | -11.34 | - | -5.08 | -3.52 | -1.46 |
Net income 1 | -11.8 | -5.151 | -5.08 | -3.52 | -1.46 |
Net margin | -62.19% | - | -34.56% | -19.66% | -6.61% |
EPS 2 | -12.77 | -1.520 | -0.8900 | -0.4500 | -0.1300 |
Free Cash Flow | - | - | - | - | - |
FCF margin | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - |
Dividend per Share | - | - | - | - | - |
Announcement Date | 7/1/19 | 6/21/23 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: March | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 | 2025 Q3 | 2025 Q4 |
---|---|---|---|---|---|---|---|---|
Net sales 1 | - | 2.731 | 3.138 | 3.98 | 4.2 | 4.25 | 4.6 | 4.86 |
EBITDA | - | - | - | - | - | - | - | - |
EBIT 1 | - | -1.208 | -0.844 | -1.02 | -0.92 | -0.94 | -0.85 | -0.65 |
Operating Margin | - | -44.23% | -26.9% | -25.63% | -21.9% | -22.12% | -18.48% | -13.37% |
Earnings before Tax (EBT) 1 | - | -1.298 | -0.923 | -1.11 | -0.96 | -0.98 | -0.89 | -0.69 |
Net income 1 | -1.418 | -1.484 | -0.866 | -1.11 | -0.96 | -0.98 | -0.89 | -0.69 |
Net margin | - | -54.34% | -27.6% | -27.89% | -22.86% | -23.06% | -19.35% | -14.2% |
EPS 2 | -0.2900 | -0.2900 | -0.0800 | -0.1700 | -0.1400 | -0.1300 | -0.1100 | -0.0800 |
Dividend per Share | - | - | - | - | - | - | - | - |
Announcement Date | 8/10/23 | 11/13/23 | 2/8/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: March | 2019 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|
Net Debt | - | - | - | - | - |
Net Cash position | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - |
Free Cash Flow | - | - | - | - | - |
ROE (net income / shareholders' equity) | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - |
Assets 1 | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - |
Capex | 0.1 | - | - | - | - |
Capex / Sales | 0.53% | - | - | - | - |
Announcement Date | 7/1/19 | 6/21/23 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+13.64% | 3.2M | |
+45.82% | 765B | |
+40.95% | 632B | |
-6.16% | 354B | |
+19.86% | 331B | |
+9.32% | 299B | |
+18.45% | 248B | |
+11.88% | 216B | |
-0.78% | 219B | |
+5.90% | 164B |
- Stock Market
- Equities
- SNOA Stock
- Financials Sonoma Pharmaceuticals, Inc.